Tozorakimab + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Viral Lung Infection and Acute Respiratory Failure
Conditions
Viral Lung Infection and Acute Respiratory Failure
Trial Timeline
Dec 13, 2022 → Jun 19, 2026
NCT ID
NCT05624450About Tozorakimab + Placebo
Tozorakimab + Placebo is a phase 3 stage product being developed by AstraZeneca for Viral Lung Infection and Acute Respiratory Failure. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05624450. Target conditions include Viral Lung Infection and Acute Respiratory Failure.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06932263 | Phase 2 | Recruiting |
| NCT05624450 | Phase 3 | Recruiting |
Competing Products
17 competing products in Viral Lung Infection and Acute Respiratory Failure